Cardiovascular Disease and Risk Management

3.2.10.0 Sec­tion 10

For the first time, this sec­tion is en­dorsed by the Amer­i­can Col­lege of Car­di­ol­o­gy. Ad­di­tion­al text was added to ac­knowl­edge heart fail­ure as an im­por­tant type of car­dio­vas­cu­lar dis­ease in peo­ple with di­a­betes for con­sid­er­a­tion when de­ter­min­ing op­ti­mal di­a­betes care.

The blood pres­sure rec­om­men­da­tions were modified to em­pha­size the im­por­tance of in­di­vid­u­alization of tar­gets based on car­dio­vas­cu­lar risk.

A dis­cus­sion of the ap­pro­pri­ate use of the ASCVD risk cal­cu­la­tor was in­cluded, and rec­om­men­da­tions were modified to in­clude as­sessment of 10-year ASCVD risk as part of over­all risk as­sessment and in de­ter­min­ing op­ti­mal treat­ment ap­proaches.

The rec­om­men­da­tion and text re­gard­ing the use of as­pirin in pri­ma­ry pre­vention was up­dated with new data.

For align­ment with the ADA-‍EASD con­sen­sus re­port, two rec­om­men­da­tions were added for the use of med­i­ca­tions that have proven car­dio­vas­cu­lar benefit in peo­ple with ASCVD, with and with­out heart fail­ure.